Iradimed (IRMD) Cost of Revenue (2013 - 2026)

Iradimed (IRMD) has reported Cost of Revenue for 14 consecutive years, with $5.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 19.13% year-over-year to $5.3 million in Q2 2026; TTM through Jun 2026 was $20.8 million, a 16.52% increase from a year earlier, with the FY2025 full-year figure at $19.5 million, up 15.38% from the prior year.
• Cost of Revenue was $5.3 million for Q2 2026 at Iradimed, up from $5.2 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $5.7 million in Q4 2025 and troughed at $2.6 million in Q2 2022.
• A 5-year average of $4.1 million and a median of $4.1 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue surged 52.76% in 2023 and fell 0.62% in 2024, its largest moves.
• Over 5 years, Cost of Revenue stood at $3.6 million in 2022, then advanced by 10.87% to $4.0 million in 2023, then increased by 14.58% to $4.6 million in 2024, then grew by 22.3% to $5.7 million in 2025, then declined by 6.25% to $5.3 million in 2026.
• The last three Cost of Revenue figures came in at $5.3 million (Q2 2026), $5.2 million (Q1 2026), and $5.7 million (Q4 2025), per Business Quant data.